Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
Christie MonahanLindsey McCoyJason G PowellJohn G GumsPublished in: The Annals of pharmacotherapy (2022)
When treating complex patients with schizophrenia, the olanzapine/samidorphan combination has limited effect on medication-induced weight gain often associated with antipsychotic olanzapine monotherapy. Additional studies are needed to further define the role of olanzapine/samidorphan in bipolar I disorder and clinical practice.
Keyphrases
- weight gain
- bipolar disorder
- chemotherapy induced
- clinical practice
- body mass index
- birth weight
- healthcare
- high glucose
- drug induced
- adverse drug
- weight loss
- randomized controlled trial
- open label
- emergency department
- combination therapy
- clinical trial
- oxidative stress
- endothelial cells
- gestational age
- drug administration